文献速递妇科

铂敏感上皮性卵巢癌腹膜复发患者肿瘤细胞减灭术后腹腔内224Ra标记微粒的首次经验

First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2025-12-04

这项1期研究在完全切除的铂敏感复发性卵巢癌患者中评估腹腔内注射α射线治疗药物Radspherin(224Ra标记微粒)的安全性和耐受性,采用3+3设计在1、2、4和7 MBq四个剂量水平递增,共纳入14例患者,未观察到剂量限制性毒性,所有剂量水平耐受良好,选择7 MBq作为扩展队列的推荐剂量。

要点

  • 14例铂敏感复发性卵巢癌患者在完全切除术后1至3天接受单次腹腔内Radspherin治疗。
  • 未观察到剂量限制性毒性,所有剂量水平耐受良好。
  • 最高活度剂量7 MBq被选为扩展队列的推荐剂量。

核心结论

  • 所有剂量水平耐受良好,未观察到剂量限制性毒性。
  • 选择最高活度剂量7 MBq作为扩展队列的推荐剂量。
  • 未报告与Radspherin相关的≥3级不良事件。

研究设计与样本

  • 1期研究,采用3+3剂量递增设计,在1、2、4和7 MBq四个剂量水平进行剂量递增。
  • 研究对象为接受完全切除的铂敏感复发性卵巢癌患者,共纳入14例。
  • Radspherin在术后1至3天单次腹腔内给药,报告12个月后的安全性和耐受性。

主要发现

  • 患者中位年龄66岁(范围56-77岁),手术开始时中位腹膜癌指数为7(范围3-16)。
  • 共报告98例治疗中出现的不良事件,其中95例为1级或2级,3例为3级。
  • 3例3级事件分别为肠梗阻(2例)和贫血(1例),研究者报告与Radspherin无关。
  • 1例2级严重不良事件为操作并发症(注射器-导管断开),报告与Radspherin相关。
  • 12个月时,无患者发生腹膜疾病进展。

关键数值与推荐

  • 剂量递增水平为1、2、4和7 MBq。
  • 最高活度剂量7 MBq被选为扩展队列的推荐剂量。
  • 未观察到剂量限制性毒性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this Phase 1 study was to evaluate safety and tolerability of the alpha emitting therapy 224Ra-labeled microparticles (Radspherin®) and to establish the recommended dose for further development. METHODS: The study was conducted in patients who had undergone complete resection of platinum-sensitive recurrent ovarian cancer. A single dose of Radspherin was administered intraperitoneally one to three days after surgery. Dose escalation (3 + 3 design) was performed at 1, 2, 4 and 7 MBq. Safety and tolerability of Radspherin after 12 months are presented. RESULTS: Fourteen patients were enrolled across the 4 dose levels. Median age was 66 (56-77) years. Median peritoneal cancer index at the start of the surgery was 7 (3-16). No dose limiting toxicity (DLT) was observed. A total of 98 treatment emergent adverse events were reported (95 grade 1 or 2, and 3 grade 3). The three grade 3 events were cases of ileus (2) and anaemia (1) and were reported as unrelated to Radspherin by the investigators. One grade 2 serious adverse event of procedural complication (disconnect syringe-catheter) was reported as related to Radspherin. At 12-months, none of the patients had experienced peritoneal disease progression. CONCLUSIONS: All dose levels were well tolerated, with no DLT observed. The highest activity dose of 7 MBq was selected as recommended dose for an expansion cohort. No grade ≥ 3 adverse events related to Radspherin were reported. CLINICAL TRIAL INFORMATION: NCT03732768.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Van Nieuwenhuysen E, Revheim ME, et al. First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer. Gynecol Oncol. 2025. PMID: 41349345. doi:10.1016/j.ygyno.2025.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。